Ribo announces authorization to start a Phase I clinical trial in Sweden for siRNA drug RBD7007 targeting Complement Factor 5, C5
On September 10, 2024, Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Ltd (Ribo) received authorization from the Swedish Medicinal Product Agency (MPA), to initiate a first-in-human (FIH) Phase I clinical trial in Sweden with the siRNA drug, RBD7007 targeting C5. This is a first-in-human (FIH) phase 1 trial to assess the safety, tolerability, and […]